NordICC colonoscopy study results should be viewed with caution—longer follow-up needed

FDA approves Shield blood test for colon cancer screening

Guardant Health Inc., a precision oncology company, announced that FDA has approved the company’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Screenings overlook hereditary genetic risk for some cancers

Current screening protocols fail to catch a notable number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome and Lynch syndrome, which increase the risk of developing certain cancers. This issue is particularly pronounced among underrepresented minorities.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Fewer than one in five eligible individuals in the United States are up-to-date with recommended lung cancer screening, according to a study led by American Cancer Society researchers.

June 14, 2024

Vol.50 No.24

Clinical Trials & Tribulations

Are we focused on the wrong risk type in genetic screening?
Breast cancer screening study shows new paths to population screening

A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.

Saudi Arabia joins International Agency for Research on Cancer

The International Agency for Research on Cancer welcomed the Kingdom of Saudi Arabia as a new participating state, underscoring the commitment to advancing cancer research and prevention in the country.

May 24, 2024

Vol.50 No.21

Clinical Roundup

A nanoparticle can penetrate the blood-brain barrier and may help to treat brain metastases

When cancer breaches the brain, it can be difficult for treatment to follow.

May 10, 2024

Vol.50 No.19

NordICC colonoscopy study results should be viewed with caution—longer follow-up needed

YOU MAY BE INTERESTED IN

FDA approves Shield blood test for colon cancer screening

Screenings overlook hereditary genetic risk for some cancers

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Are we focused on the wrong risk type in genetic screening?
Breast cancer screening study shows new paths to population screening

Saudi Arabia joins International Agency for Research on Cancer

A nanoparticle can penetrate the blood-brain barrier and may help to treat brain metastases

Renew today!

Subscriber content

Login

NordICC colonoscopy study results should be viewed with caution­—longer follow-up needed

YOU MAY BE INTERESTED IN

FDA approves Shield blood test for colon cancer screening

Screenings overlook hereditary genetic risk for some cancers

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening

Saudi Arabia joins International Agency for Research on Cancer

A nanoparticle can penetrate the blood-brain barrier and may help to treat brain metastases

Login

NordICC colonoscopy study results should be viewed with caution—longer follow-up needed

Are we focused on the wrong risk type in genetic screening?
Breast cancer screening study shows new paths to population screening